Company News
Strides Completes ₹1,000M Pivot Path Stake Sale
Strides Pharma completed the sale of its majority stake in subsidiary Pivot Path to Ascent Capital-led consortium for ₹1,000 million.
The company received ₹750 million upfront, with ₹250 million defer
